Gefitinib

Iressa (gefitinib) is a tyrosine kinase inhibitor indicated for metastatic non-small cell lung cancer (NSCLC) that has certain epidermal growth factor receptor (EGFR) mutations. Iressa label contains warnings for interstitial lung disease (ILD), hepatotoxicity, gastrointestinal perforation, diarrhea, ocular disorders including keratitis, bullous and exfoliative skin disorders, and embryofetal toxicity.